Drug recall · June 10, 2026
Duloxetine DR Capsules recall
Why: CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc.
- Lots / codes
Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026
- Quantity
- 50 bottles
- Company
- Asclemed USA Inc., Torrance, CA
- Distribution
- US Nationwide.
- Initiated
- May 14, 2026 · Voluntary: Firm initiated
- Classified
- June 2, 2026
- Reported
- June 10, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.